InflaRx N.V (IF0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InflaRx N.V (IF0) has a cash flow conversion efficiency ratio of -0.199x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-9.04 Million ≈ $-10.57 Million USD) by net assets (€45.37 Million ≈ $53.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
InflaRx N.V - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how InflaRx N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read InflaRx N.V total liabilities for a breakdown of total debt and financial obligations.
InflaRx N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InflaRx N.V ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinher Technology Inc
TW:4999
|
0.014x |
|
Deswell Industries Inc
NASDAQ:DSWL
|
0.021x |
|
Broadway Financial Corporation
NASDAQ:BYFC
|
-0.009x |
|
Centrepoint Alliance Ltd
AU:CAF
|
0.231x |
|
FingerMotion Inc
NASDAQ:FNGR
|
-0.034x |
|
TronicS Microsystems SA
PA:ALTRO
|
-0.435x |
|
Azimut Exploration Inc.
V:AZM
|
-0.039x |
|
Neo Battery Materials Ord Shs
V:NBM
|
-0.601x |
Annual Cash Flow Conversion Efficiency for InflaRx N.V (2016–2024)
The table below shows the annual cash flow conversion efficiency of InflaRx N.V from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see IF0 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €61.42 Million ≈ $71.80 Million |
€-48.56 Million ≈ $-56.77 Million |
-0.791x | -114.48% |
| 2023-12-31 | €102.58 Million ≈ $119.93 Million |
€-37.81 Million ≈ $-44.21 Million |
-0.369x | +3.49% |
| 2022-12-31 | €88.35 Million ≈ $103.29 Million |
€-33.74 Million ≈ $-39.45 Million |
-0.382x | -0.68% |
| 2021-12-31 | €105.28 Million ≈ $123.08 Million |
€-39.94 Million ≈ $-46.69 Million |
-0.379x | +19.14% |
| 2020-12-31 | €77.86 Million ≈ $91.03 Million |
€-36.53 Million ≈ $-42.70 Million |
-0.469x | -16.34% |
| 2019-12-31 | €107.15 Million ≈ $125.27 Million |
€-43.20 Million ≈ $-50.51 Million |
-0.403x | -183.28% |
| 2018-12-31 | €151.39 Million ≈ $176.99 Million |
€-21.55 Million ≈ $-25.19 Million |
-0.142x | -39.89% |
| 2017-12-31 | €119.43 Million ≈ $139.63 Million |
€-12.15 Million ≈ $-14.21 Million |
-0.102x | -152.36% |
| 2016-12-31 | €-25.69 Million ≈ $-30.03 Million |
€-4.99 Million ≈ $-5.84 Million |
0.194x | -- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal … Read more